Lapatinib and Circulating Tumor Cells in Breast Cancer

Sponsor
University Hospital of Crete
Study ID
NCT00694252
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lapatinib — DRUG
    Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.

Study Details

This study will evaluate the efficacy of lapatinib in eradicating chemo- resistant tumour cells circulating in the blood of patients with breast cancer.

Key Dates

Start date
Jul 31, 2008
Status verified
Sep 2015
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Lapatinib

Primary Outcome Measure

Efficacy of lapatinib by quantitative analysis of circulating tumour cells in the blood.The efficacy will be measured before, during and after the completion of treatment [ Time Frame: 2 months ]

Related Studies